3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
28
Neoplasm Metastasis
9
Neoplasms
8
Brain Neoplasms
5
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Glioma
3
Endometrial Neoplasms
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Meningioma
2
Liposarcoma
2
Head and Neck Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
116
daratumumab
68
Lenalidomide
67
Bortezomib
55
pomalidomide
45
carfilzomib
40
Cyclophosphamide
33
Calcium Dobesilate
32
Specimen Handling
30
Biopsy
28
Magnetic Resonance Spectroscopy
25
isatuximab
20
belantamab mafodotin
20
talquetamab
17
iberdomide
17
fludarabine
17
Melphalan
15
dexamethasone acetate
14
dexamethasone 21-phosphate
14
auricularum
14
fludarabine phosphate
11
selinexor
10
elotuzumab
10
tocilizumab
9
X-Rays
8
Nivolumab
8
trametinib
7
Sirolimus
7
Whole-Body Irradiation
6
Mycophenolic Acid
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
abemaciclib
×
90 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled